Literature DB >> 15260942

Integrating pharmacotherapy and psychotherapy in the management of anxiety disorders.

John M Kuzma1, Donald W Black.   

Abstract

Anxiety disorders are among the most prevalent psychiatric conditions throughout the world, and they are responsible for considerable morbidity and functional impairment. Patients with these disorders make extensive use of medical resources, not only through their use of the mental health system but by frequent utilization of primary care and emergency medical services. Although it is common clinical practice to combine pharmacotherapy and psychotherapy, some researchers have argued that this has not been shown effective in practice and is an inefficient use of limited mental health resources. This article will examine the evidence supporting integrative therapy for the major Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision anxiety disorders and discuss clinical considerations surrounding the use of combined therapies for anxiety.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15260942     DOI: 10.1007/s11920-004-0076-y

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   8.081


  28 in total

Review 1.  Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety.

Authors:  J C Ballenger; J R Davidson; Y Lecrubier; D J Nutt; T D Borkovec; K Rickels; D J Stein; H U Wittchen
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

2.  A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder.

Authors:  J Cottraux; E Mollard; M Bouvard; I Marks; M Sluys; A M Nury; R Douge; P Cialdella
Journal:  Int Clin Psychopharmacol       Date:  1990-01       Impact factor: 1.659

Review 3.  Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination?

Authors:  Edna B Foa; Martin E Franklin; Jason Moser
Journal:  Biol Psychiatry       Date:  2002-11-15       Impact factor: 13.382

4.  Economic costs of anxiety disorders.

Authors:  R L DuPont; D P Rice; L S Miller; S S Shiraki; C R Rowland; H J Harwood
Journal:  Anxiety       Date:  1996

5.  Open trial of interpersonal psychotherapy for the treatment of social phobia.

Authors:  J D Lipsitz; J C Markowitz; S Cherry; A J Fyer
Journal:  Am J Psychiatry       Date:  1999-11       Impact factor: 18.112

6.  A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.

Authors:  C J McDougle; C N Epperson; G H Pelton; S Wasylink; L H Price
Journal:  Arch Gen Psychiatry       Date:  2000-08

7.  Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial.

Authors:  D H Barlow; J M Gorman; M K Shear; S W Woods
Journal:  JAMA       Date:  2000-05-17       Impact factor: 56.272

8.  Diazepam versus alprazolam for the treatment of panic disorder.

Authors:  R Noyes; G D Burrows; J H Reich; F K Judd; M J Garvey; T R Norman; B L Cook; P Marriott
Journal:  J Clin Psychiatry       Date:  1996-08       Impact factor: 4.384

9.  Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study.

Authors:  Umberto Albert; Eugenio Aguglia; Giuseppe Maina; Filippo Bogetto
Journal:  J Clin Psychiatry       Date:  2002-11       Impact factor: 4.384

10.  Treatment of phobias. I. Comparison of imipramine hydrochloride and placebo.

Authors:  C M Zitrin; D F Klein; M G Woerner; D C Ross
Journal:  Arch Gen Psychiatry       Date:  1983-02
View more
  5 in total

1.  Combined pharmacotherapy and psychotherapy for social anxiety disorder.

Authors:  Dan J Stein; Jonathan C Ipser
Journal:  Curr Psychiatry Rep       Date:  2010-08       Impact factor: 5.285

2.  Combined use of behavioral therapy and partial NMDA agonist to treat anxiety disorders.

Authors:  Dan J Stein
Journal:  Curr Psychiatry Rep       Date:  2006-08       Impact factor: 5.285

3.  Generalized anxiety and C-reactive protein levels: a prospective, longitudinal analysis.

Authors:  W E Copeland; L Shanahan; C Worthman; A Angold; E J Costello
Journal:  Psychol Med       Date:  2012-04-30       Impact factor: 7.723

4.  Increased error-related brain activity distinguishes generalized anxiety disorder with and without comorbid major depressive disorder.

Authors:  Anna Weinberg; Daniel N Klein; Greg Hajcak
Journal:  J Abnorm Psychol       Date:  2012-05-07

Review 5.  Pharmacotherapy of anxiety disorders: a critical review.

Authors:  Nastassja Koen; Dan J Stein
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.